Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Andrew C Adams"'
Autor:
Garima Singhal, Ffolliott Martin Fisher, Melissa J Chee, Tze Guan Tan, Abdelfattah El Ouaamari, Andrew C Adams, Robert Najarian, Rohit N Kulkarni, Christophe Benoist, Jeffrey S Flier, Eleftheria Maratos-Flier
Publikováno v:
PLoS ONE, Vol 11, Iss 2, p e0148252 (2016)
Fibroblast growth factor 21 (FGF21) is an important endocrine metabolic regulator expressed in multiple tissues including liver and adipose tissue. Although highest levels of expression are in pancreas, little is known about the function of FGF21 in
Externí odkaz:
https://doaj.org/article/2cc77fd5d08448eea0fb183f58d511fd
Autor:
Airlia C S Thompson, Matthew D Bruss, Nitish Nag, Alexei Kharitonenkov, Andrew C Adams, Marc K Hellerstein
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e111418 (2014)
Calorie restriction (CR) delays aging and extends lifespan in numerous organisms, including mice. Down-regulation of the somatotropic axis, including a reduction in insulin-like growth factor-1 (IGF-1), likely plays an important role in CR-induced li
Externí odkaz:
https://doaj.org/article/e39653efec1a4b69b6978d55a755d744
Autor:
Andrew C Adams, Carolyn A Halstead, Barbara C Hansen, Armando R Irizarry, Jennifer A Martin, Sharon R Myers, Vincent L Reynolds, Holly W Smith, Victor J Wroblewski, Alexei Kharitonenkov
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e65763 (2013)
Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator that represents a promising target for the treatment of several metabolic diseases. Administration of recombinant wild type FGF21 to diabetic animals leads to a dramatic improvement i
Externí odkaz:
https://doaj.org/article/aa7072c111da48b3972a0347777f6348
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e49977 (2012)
FGF21 has gradually become a focal point in metabolic research given its intriguing and complex biology and relevance to drug discovery. Despite the large amount of accumulated data, there remains a dearth of understanding of FGF21 physiology at the
Externí odkaz:
https://doaj.org/article/facef5957cc24fec89188c2d2fbf38f5
Autor:
Andrew C Adams, Tamer Coskun, Armando R Irizarry Rovira, Michael A Schneider, David W Raches, Radmila Micanovic, Holly A Bina, James D Dunbar, Alexei Kharitonenkov
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e38438 (2012)
Fibroblast growth factors 19 (FGF19) and 21 (FGF21) have emerged as key regulators of energy metabolism. Several studies have been conducted to understand the mechanism of FGF19 and FGF21 action, however, the data presented has often been inconsisten
Externí odkaz:
https://doaj.org/article/83545c5b932f44aa84d465c8ea358ac7
Autor:
Ricardo J. Samms, Christine C. Cheng, Marcel Fourcaudot, Sami Heikkinen, Ahmed Khattab, John Adams, Eugenio Cersosimo, Curtis Triplitt, Curtis Puckett, Kostas Tsintzas, Andrew. C. Adams, Muhammad A. Abdul-Ghani, Ralph A. DeFronzo, Luke Norton
Publikováno v:
American journal of physiology. Endocrinology and metabolism. 323(2)
Fibroblast growth factor 21 (FGF21) is increased acutely by carbohydrate ingestion and is elevated in patients with type 2 diabetes (T2D). However, the physiological significance of increased FGF21 in humans remains largely unknown. We examined wheth
Autor:
Guannan Li, Hanqing Chen, Feng Shen, Steven Blake Smithson, Gavyn Lee Shealy, Qinggong Ping, Zerong Liang, Jingyan Han, Andrew C. Adams, Yu Li, Dechun Feng, Bin Gao, Masahiro Morita, Xianlin Han, Tim H. Huang, Nicolas Musi, Mengwei Zang
Publikováno v:
Hepatology.
Autor:
Jack Knorr, Russell Perry, Peter Chen, Corey Hebert, Richard E. Higgs, Mark D. Williams, Joseph Boscia, Bharat Mocherla, Masoud Azizad, Princy Kumar, Robert L. Gottlieb, Paul Klekotka, Dipak R. Patel, Ajay Nirula, Imad Shawa, Andra L. Blomkalns, Andrew C. Adams, Gregory D. Huhn, Kenneth L. Custer, Lei Shen, Timothy R. Holzer, Jason Morris, Philip J. Ebert, Andrew E. Schade, Jacob Van Naarden, Blaze investigators, Gerard J. Oakley, Jose Cardona, Janelle Sabo, Matan C. Dabora, Daniel Skovronsky, Chad Crystal, Barry Heller, Awawu Igbinadolor, Michael Dougan
Publikováno v:
Clinical Infectious Diseases. 75:e440-e449
Background Based on interim analyses and modeling data, lower doses of bamlanivimab and etesevimab together (700/1400 mg) were investigated to determine optimal dose and expand availability of treatment. Methods This Phase 3 portion of the BLAZE-1 tr
Autor:
Gregory D. Huhn, Dipak R. Patel, Bharat Mocherla, Daniel Skovronsky, Kenneth L. Custer, Paul Klekotka, Imad Shawa, Andrew E. Schade, Janelle Sabo, Nicole L. Kallewaard, Michael Durante, Andrew C. Adams, Timothy R. Holzer, Ajay Nirula, Joseph Boscia, Masoud Azizad, Jose Cardona, Princy Kumar, Chad Crystal, Lei Shen, Peter Chen, Russell Perry, Corey Hebert, Richard E. Higgs, Robert L. Gottlieb, Matan C. Dabora, Philip J. Ebert, Jacob Van Naarden, Gerard J. Oakley, Jason Morris, Michael Dougan, Awawu Igbinadolor, Barry Heller
Publikováno v:
The New England Journal of Medicine
Background Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive i
Autor:
Olivier Benichou, Tamer Coskun, Malgorzata D. Gonciarz, Parag Garhyan, Andrew C. Adams, Yu Du, James D. Dunbar, Jennifer A. Martin, Kieren J. Mather, Richard T. Pickard, Vincent L. Reynolds, Deborah A. Robins, Simbarashe P. Zvada, Paul J. Emmerson
Publikováno v:
Cell Metabolism. 35:274-286.e10